Radiotracers for imaging P-glycoprotein function

Details Radiotracers for imaging P-glycoprotein function Radiotracers for imaging P-glycoprotein function

2011-08-02

2011-08-02

Andres, Janet (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S327000

Reexamination Certificate

active

07989630

ABSTRACT:
P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established or prospective chemotherapeutics (a phenomenon known as multidrug resistance). This invention concerns the preparation and use of radiotracers for imaging P-gp function in vitro and in vivo. Radiotracers of the present invention are avid substrates for P-gp and have structures based on N-Desmethyl-loperamide.

REFERENCES:
patent: WO 03/037340 (2002-05-01), None
patent: WO 2004/075926 (2004-09-01), None
patent: WO 2005/080992 (2005-09-01), None
patent: WO 2006/036994 (2006-04-01), None
Zoghbi, et. al. “[11C]Loperamide and its N-desmethyl radiometabolite are avid substrates for brain Pglycoprotein efflux” Journal of Nuclear Medicine, May 1, 2007, 48 (Supplement 2):248P, Neurosciences: Basic Science Basic Science Posters, abstract 1149.
Lazarova, et. al. “Synthesis and 11C-labeling of N-Desmethyl-loperamide as a prospectively advantageous PET radiotracer for assessing brain P-gp function.” Journal of Nuclear Medicine, May 1, 2007, 48 (Supplement 2):300P, Neurosciences: Basic Science Basic Science Posters, abstract 1329.
Choo, Edna F. et al.; “Differential in Vivo Sensitivity to Inhibition of P-glycoprotein located in Lymphocytes, Testes, and the Blood-Brain Barrier”; 2006,The Journal of Pharmacology and Experimental Therapeutics, vol. 317, No. 3, pp. 1012-1018.
Croucher, Martin J. et al.; “Inhibition of the development of electrical kindling of the prepyriform cortex by daily focal injections of excitatory amino acid antagonists”; 1988,European Journal of Pharmacology, vol. 152, pp. 29-38.
Ganbmann, B. et al.; “Simultaneous Determination of Loperamide and its Desmethylated Metabolites in Plasma and Urine by High-Performance Liquid Chromatography—Atmospheric-Pressure Ionization Mass Spectrometry”; 2001,Chromatographia, vol. 53, pp. 656-660.
He, Huaibing et al.; “Quantitation of loperamide and N-demethyl-loperamide in human plasma using electrospray ionization with selected reaction ion monitoring liquid chromatography—mass spectrometry”; 2000,Journal of Chromatography, vol. 744, pp. 323-331.
Heykants, J.J. P. et al.; “The Excretion and Metabolism of the Antidiarrhoel Loperamide in the Wistar Rat”; 1977,European Journal of Drug Metabolism and Pharmacokinetics, No. 2, pp. 81-91.
Johansen, Sys Stybe et al.; “Liquid chromatography—tandem mass spectrometry determination of lopermide and its main metabolite desmethylloperamide in biological specimens and application to forensic cases”; 2004,Journal of Chromatography, vol. B811, pp. 31-36.
Kalgutkar, Amit S. et al.; “Identification of anN-methyl-4-Phenylpyridinium-like Metabolite of the Antidiarrheal Agent Loperamide in Human Liver Microsomes: Underlying Reason(s) for the lack of Neurotoxicity Despite the Bioactivation Event”; 2004,Drug Metabolism and Disposition, vol. 32. No. 9, pp. 943-952.
Mikus, Gerd et al.; “Reduction of Saquinavir Exposure by Coadministration of Lopermide”; 2004,Clin. Pharmacokinet, vol. 43, No. 14, pp. 1015-1024.
Miyazaki, Hisashi et al.; “Disposition and metabolism of h [14C]loperamide in rats”; 1979,European Journal of Metabolism and Pharmacokinetics, vol. 4, pp. 199-206.
Miyazaki, Hisashi et al.; “Loperamide in Rat Intestines: A Unique Disposition”; 1982,Life Sciences, vol. 30, pp. 2203-2206.
Mukwaya, Geoffrey et al.; “Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers”; 2005,Antimicrobial Agents and Chemotherapy, vol. 49, No. 12, pp. 4903-4910.
Niemi, Mikko et al.; “Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide”; 2006,European Journal of Clinical Pharmacology, vol. 62, pp. 463-472.
Sadeque, Abu J. M. et al.; “Increased drug delivery to the brain by P-glycoprotein inhibition”; 2000,Clinical Pharmacology and Therapeutics, pp. 231-237.
Schinkel, Alfred H. et al.; “P-Glycoprotein in the Blood-Brain Barrier of Mice Influences the Brain Penetration and Pharmacological Activity of Many Drugs”; 1996,J. Clin. Invest., vol. 97, No. 11, 2517-2524.
Sklerov, Jason e tal.; “Tissue Distributin of Loperamide and N-Desmethylloperamide Follow a Fatal Overdose”; 2005,Journal of Analytical Toxicology, vol. 29, pp. 750-754.
Tayrouz, Yorki et al.; “Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement”; 2001,Clinical Pharmacology and Therapeutics, vol. 70, No. 5, pp. 405-414.
Yoshida, Koji et al.; “Metabolites of Loperamide in Rats”; 1979,Biomedical Mass Spectrometry, vol. 6, No. 6, pp. 253-259.
Weiss, Johanna; Evaluation of Inhibitory Potencies for Compounds Inhibiting P-Glycoprotein but without maximum effects:F2values 2006,Drug Metabolism and Disposition, vol. 34, No. 2, pp. 203-207.
Zoghbi, Sami S. et al.,11C-Loperamide and itsN-DesmethylRadiometabolite Are Avid Substrates for Brain Permeability—Glycoprotein Efflux; 2008,Journal of Nuclear Medicine, pp. 649-656.
Klasner, B.D. et al., “Small animal 18F-FDG PET in vivo imaging of the penumbra in mice.”, Neurosciences, p. 248P, abstract 1148, 1 page, 2007.
Lazarova, N. et al., “Synthesis and 11C-labeling of N-Desmethyl-loperamide as a prospectively advantageous PET radiotracer for assessing brain P-gp function.”, Neurosciences, p. 300P, abstract 1329. 1 page, 2007.
Liow, J.S. et al., “P-glycoprotein Function Imaged with [11C]N-Desmethyl-Loperamide in Monkey”, NIMH, 1 page, first published online in 2008.
Seneca, N., “Inhibition of Metabolism of [11C]Loperamide in Mouse by the Potent CYP3A4 Inhibitor, Ketoconazole”, NeuroImage 2008, vol. 412, Supplement 2 (T100), 1 page.
Zoghbi, S.S., “[11C]N-Desmethyl-Loperamide is an Improved Radiotracer with Potential for Measuring Brain P-gp Function”, NeuroImage 2008, vol. 412, Supplement 2 (T106), 1 page.

Affiliated with

Also associated with

Rating

Radiotracers for imaging P-glycoprotein function does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radiotracers for imaging P-glycoprotein function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiotracers for imaging P-glycoprotein function will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2665880